Prof. Dr. med. Martin Schrappe
Facts
Phone:
+49-431-500-20102
Website:
Affiliations:
Clinic for Pediatrics and Adolescent Medicine I / University Medical Center Schleswig-Holstein, Campus Kiel
Address:
Arnold-Heller-Str. 3, Bldg C, 24105 Kiel
Curriculum vitae
Education/Training
Since 12/2004 | Director of Pediatrics I, Christian-Albrechts-University Kiel, Medical Center Schleswig-Holstein, Campus Kiel, Germany |
1996 -2004 | Senior Attending Physician, Dept. of Pediatric Hematology and Oncology, MHH, Hannover, Germany (head: Prof. Dr. K. Welte) |
1985-87, 90-96 | Resident, Children’s Hospital, MHH, Hannover, Germany |
12/1985 | Dr. med. (Thesis in medicine) |
1977-1984 | Medical School, Universities of Würzburg and Hamburg, Germany |
Research Experience/Academic Appointments
Since 12/2004 | Full Professor (C4) of Pediatrics, Christian-Albrechts-University, Kiel, Germany |
2000 | Associate Professor (C3) for Pediatric Hematology/Oncology, Medical School Hannover |
1987-1990 | DFG Research Fellow, Division of Tumor Cell Biology, Dept. of Immunology (head: Dr. R.A. Reisfeld, Ph.D.), The Scripps Research Institute, La Jolla, CA, USA |
Important Scientific Prizes / Selected Functions
Since 2019 | Chairman of Society of Ped. Hematology and Oncology, Germany/Austria (GPOH) |
2016-2018 | President, SIOP-Europe |
2001-2016 | Chairman, International BFM Study Group |
Since 2017 | Principal Investigator, trial AIEOP-BFM ALL 2017 |
2009-2016 | Principal Investigator, trial AIEOP-BFM ALL 2009 |
02/2014 | Deutscher Krebspreis, Deutsche Krebsgesellschaft (German Cancer Society) |
Since 2009 | Member or Chair of DSMC, e.g. DCOG ALL-10, DCOG ALL-11, ALLTogether |
03/1999 | “Leukemia Clinical Research Award 1999” of the German Society of Hematology and Oncology (DGHO) |
Project-related publications
P1, P3, P6, P7, Z
The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis
P1, P3, P4, INF, Z
The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age
P3, P4, P6, P7, Z
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL
P3, P6, P7, Z
Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia
P1, P3, P6, Z
CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia
P1, P6, P7, Z
Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia
P1, P3, P4, Z
PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia
P1, P3, P4, Z